Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 78 of 1,261
  1. US 12162949

    CD38 antibody

    BLACK BELT THERAPEUTICS LIMITED Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  2. US 12161733

    Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  3. US 12162818

    Inhibitors of the n-terminal domain of the androgen receptor

    The United States Government represented by the Department of Veterans Affairs Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  4. US 12161702

    Methods and compositions for CNS delivery of heparan N-sulfatase

    Takeda Pharmaceutical Company Limited Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  5. US 12161674

    CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

    Vertex Pharmaceuticals Incorporated Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  6. US 12162920

    Hinge area and use of same in constructing car skeleton

    CHONGQING PRECISION BIOTECH COMPANY LIMITED Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  7. US 12162838

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  8. US 12161755

    Sustained release device for treatment of Parkinson's disease and other disorders

    Regents of the University of Minnesota Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  9. US 12161097

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  10. US 12162943

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  11. US 12161655

    Methods of treating mycobacterial infections using tetracycline compounds

    United States Government as represented by the Department of Veterans Affairs Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  12. US 12162912

    Proteins for blocking neurotransmitter release

    The Regents of the University of Colorado, a Body Corporate Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  13. US 12162997

    Facile assembly of soft nanoarchitectures and co-loading of hydrophilic and hydrophobic molecules via flash nanoprecipitation

    Northwestern University Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  14. US 12162910

    Recombinant gp120 protein with V1-loop deletion

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  15. US 12162950

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  16. US 12162870

    Anticancer compounds

    The Regents of the University of California Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  17. US 12161696

    Methods of treating hemophilic arthropathy using chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  18. US 12161717

    CD38 modulating antibody agents

    BLACK BELT THERAPEUTICS LIMITED Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  19. US 12161664

    Tetrathionate for cyanide and methylmercaptan poisoning

    The Regents of the University of California Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  20. US 12162821

    Treatment of cataplexy

    AXSOME MALTA LTD. Β· Granted Dec 10, 2024 Β· Expires Dec 5, 2044

    granted
  21. US 2024398790

    TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB

    ABBVIE INC [US] Β· Granted Dec 5, 2024 Β· Expires Nov 30, 2044

    granted
  22. WO 2024249615

    EXOSOMES DE LAIT BOVIN POUR ADMINISTRER DE LA VITAMINE D

    ABBOTT LAB [US] Β· Granted Dec 5, 2024 Β· Expires Nov 30, 2044

    granted
  23. WO 2024249235

    CONJUGUÉS ANTICORPS-MÉDICAMENT D'AGENT DE DÉGRADATION DE BET ANTI-CD33 HUMAIN

    ABBVIE INC [US] Β· Granted Dec 5, 2024 Β· Expires Nov 30, 2044

    granted
  24. US 12159700

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. Β· Granted Dec 3, 2024 Β· Expires Nov 28, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.